Blood cancer drug safety tracked over 5 years

NCT ID NCT07162181

First seen Oct 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It is for those who completed an earlier study and are still benefiting from the treatment. Participants will receive the drug every 12 weeks for about 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer hospital

    Beijing, 100142, China

  • Blood Institute of the Chinese Academy of Medical science

    Tianjin, 300020, China

  • Harbin Medical University Cancer Hospital

    Harbin, 150081, China

  • Shanghai East Hospital

    Shanghai, 200123, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, 510060, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430022, China

Conditions

Explore the condition pages connected to this study.